Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bladder Cancer AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: Bladder Cancer AND Cancer. Displaying page 7 of 19.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2011-002424-41 Sponsor Protocol Number: OGX-427-02 Start Date*: 2011-11-22
    Sponsor Name:OncoGenex Technologies, Inc.
    Full Title: A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
    Medical condition: Metastatic or locally inoperable, advanced (T4b, N2, N3 or M1) transitional cell carcinoma (TCC) of the urinary tract (bladder, urethra, ureter and renal pelvis)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005084 Bladder transitional cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-004112-28 Sponsor Protocol Number: URO-EMDA-2022-1 Start Date*: 2023-03-27
    Sponsor Name:Guillem Abad Carratalà
    Full Title: Randomized prospective study of the impact of preoperative instillation of mitomycin-C by electromotive drug administration (EMDA) in patients with non-muscle-infiltrating urothelial carcinoma
    Medical condition: Non muscle invasive bladder tumor
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005009 Bladder cancer stage I, without cancer in situ PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002979-26 Sponsor Protocol Number: D419JC00001 Start Date*: 2018-07-16
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non Musc...
    Medical condition: Non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005008 Bladder cancer stage I, with cancer in situ PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Restarted) FR (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001443-27 Sponsor Protocol Number: CA209-6E8,CNN-BC Start Date*: 2021-11-02
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer. (CA209-6E8, C...
    Medical condition: Patients with non-metastatic muscle invasive bladder cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066753 Bladder transitional cell carcinoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003344-21 Sponsor Protocol Number: 7465-CL-0301 Start Date*: 2019-05-27
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
    Medical condition: Locally advanced or metastatic urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) BE (Completed) AT (Completed) DK (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PT (Trial now transitioned) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005428-99 Sponsor Protocol Number: 08/0365 Start Date*: 2009-10-19
    Sponsor Name:University College London
    Full Title: A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive b...
    Medical condition: Non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005006 Bladder cancer stage 0, with cancer in situ LLT
    9.1 10005007 Bladder cancer stage 0, without cancer in situ LLT
    9.1 10005008 Bladder cancer stage I, with cancer in situ LLT
    9.1 10005009 Bladder cancer stage I, without cancer in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004023-20 Sponsor Protocol Number: MK-3475-992 Start Date*: 2020-02-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Pa...
    Medical condition: Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IE (Completed) DK (Prematurely Ended) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002311-34 Sponsor Protocol Number: MK-3475-672(INCB24360-ECHO-307) Start Date*: 2017-12-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Randomized, Double-blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-6...
    Medical condition: Bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Temporarily Halted) NL (Completed) GB (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002449-39 Sponsor Protocol Number: 42756493BLC2003 Start Date*: 2020-07-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Inva...
    Medical condition: Cohort 1 and 2: High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusions Cohort 3 Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) with FGFR Mutations or Fusi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) PL (Trial now transitioned) BE (Completed) FR (Trial now transitioned) CZ (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002372-18 Sponsor Protocol Number: 515 Start Date*: 2006-09-11
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: Pilot Study of the Intravesical Administration of EOquin Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer.
    Medical condition: Bladder Cancer Stage 1 without Cancer in Situ Patients will have transitional-cell carcinoma of the bladder, clinical TNM stage Ta or T1 and histologic grade G1 or G2 before transurethral resection.
    Disease: Version SOC Term Classification Code Term Level
    9 10005009 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-000205-24 Sponsor Protocol Number: G1T28-209 Start Date*: 2021-10-28
    Sponsor Name:G1 Therapeutics, Inc.
    Full Title: A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Meta...
    Medical condition: Untreated, Locally Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003479-78 Sponsor Protocol Number: SGN22E-001 Start Date*: 2018-08-29
    Sponsor Name:Seattle Genetics Inc.
    Full Title: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoin...
    Medical condition: Patients with locally advanced or metastatic urothelial cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10077056 Urothelial carcinoma recurrent LLT
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    21.0 100000004864 10046715 Urothelial carcinoma bladder recurrent LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    21.0 100000004864 10046725 Urothelial carcinoma ureter metastatic LLT
    21.0 100000004864 10046726 Urothelial carcinoma ureter recurrent LLT
    21.0 100000004864 10046730 Urothelial carcinoma urethra metastatic LLT
    21.0 100000004864 10046731 Urothelial carcinoma urethra recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004356-30 Sponsor Protocol Number: PCYC-1145-LT Start Date*: 2020-03-11
    Sponsor Name:Pharmacyclics Switzerland GmbH, an AbbVie company
    Full Title: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043515 Throat cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054695 Waldenstrom's macroglobulinemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042080 Stomach cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041152 Small lymphocytic lymphoma, consistent with CLL (Working Formulation) LLT
    20.0 100000004870 10018799 GVHD LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) GR (Completed) CZ (Trial now transitioned) DE (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002265-15 Sponsor Protocol Number: BO44157 Start Date*: 2023-03-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, MULTICENTER, OPEN LABEL, CONTROLLED STUDY OF RO7247669 ALONE OR IN COMBINATION WITH TIRAGOLUMAB VERSUS ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR...
    Medical condition: Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001807-35 Sponsor Protocol Number: GETUG-AFU35UC-0160-1715 Start Date*: 2018-10-08
    Sponsor Name:UNICANCER
    Full Title: Phase II study of maintenance anti-PD-L1 treatment with atezolizumab after chemo-radiotherapy for muscle-infiltrating bladder cancer patients not eligible for radical cystectomy: Bladder Sparing
    Medical condition: Patients older than ≥18 years, muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient’s refusal.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003026-69 Sponsor Protocol Number: IO102-IO103-022 Start Date*: 2022-05-09
    Sponsor Name:IO Biotech ApS
    Full Title: A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung ...
    Medical condition: Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046722 Urothelial carcinoma bladder stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020397-42 Sponsor Protocol Number: UROL2008/5 Start Date*: 2010-12-22
    Sponsor Name:VUmc Dept Urology
    Full Title: The efficacy of an antigenic marker lesion for the therapeutic effect in patients with multiple, Ta/T1, G1/G2, non-muscle invasive bladder cancer (NMIBC) treated with TUR followed by IL-2 instillation
    Medical condition: Multiple, Ta / T1, G1 / G2, non-muscle invasive bladder carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004390-28 Sponsor Protocol Number: Alexander Becherer Start Date*: 2005-03-02
    Sponsor Name:Univ.-Kl.f.Nuklearmedizin Wien
    Full Title: 11C-Acetate PET and 18F-Choline PET in Bladder Carcinoma: Prospective Validation for the Preoperative Staging
    Medical condition: Patients with bladder carcinoma who are candidates for surgery. Patients with lymph node metastases benefit from preoperative chemotherapy but in case of negative lymph nodes they undergo a toxic t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001112-35 Sponsor Protocol Number: 010463QM Start Date*: 2015-11-09
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder
    Medical condition: T2T4N0M0 transitional cell carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066753 Bladder transitional cell carcinoma stage II PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066754 Bladder transitional cell carcinoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066752 Bladder transitional cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Prematurely Ended) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000695-28 Sponsor Protocol Number: VitDURO-AECC17-01 Start Date*: 2018-07-04
    Sponsor Name:Hospital Universitari Germans Trias i Pujol
    Full Title: Pilot study of Vitamin D biological effects in patients with resectable urinary tract urothelial carcinoma.
    Medical condition: Patients with resectable urinary tract urothelial carcinoma candidates to radical cystectomy o nephroureterectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046718 Urothelial carcinoma bladder stage I, with cancer in situ LLT
    20.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    20.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    20.0 100000004864 10046724 Urothelial carcinoma ureter local LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 15:39:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA